Literature DB >> 10217313

Formulation and biological activity of antineoplastic proteoglycans derived from Mycobacterium vaccae in chitosan nanoparticles.

X X Tian1, M J Groves.   

Abstract

Although heat-killed suspensions of Mycobacterium vaccae have been tested clinically against tuberculosis and cancer, from a pharmaceutical perspective it would be advantageous to utilize isolated active components rather than the heat-degraded bacterial materials. In our laboratory we have isolated from M. vaccae a number of high-molecular-weight proteoglycans with considerable immunological and antineoplastic activity. The structure of one of these, PS4A, obtained by extraction with boiling water, seems to consist of a basic unit with a 20-kDa protein core to which are attached glucans and O-methylated 4-kDa polysaccharides. The molecular weight is (approx.) 50 kDa, but because of self-association, that of the recovered high-molecular-weight fraction is greater than 150 kDa. A similar, but even larger, molecule (PS4alpha, MW approximately 20 MDa) is obtained by cold extraction with 8 M urea. Both are active in-vivo against an S-180 murine sarcoma model but have no activity in-vitro, suggesting an antitumour effect involving activated macrophages. For this reason gelatin nanoparticles are unsuitable as a vehicle but chitosan seemed to be a promising alternative. In this report we describe the production of stable 600-700-nm diameter nanoparticles of chitosan without organic solvents. Adsorption and release of bovine serum albumin seemed to be affected by the charge of the two reactants and at high doses not all adsorbate was released. PS4A, because of structural and compositional differences, had to be loaded on to the chitosan by freeze drying a suspension of the nanoparticles in a solution of the drug. After a rapid (burst) release phase, the rate of release into water was steady for the next 4 h, but not all the drug was released. In-vivo it was evident that PS4A and PS4alpha were equally active in solution or when formulated in the chitosan nanoparticles. These results show that chitosan nanoparticles, readily prepared without the use of organic solvents, are a suitable vehicle for the delivery of these immunostimulants from M. vaccae; the formulations might find application as antitumour agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217313     DOI: 10.1211/0022357991772268

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

Review 1.  Recent advances of chitosan nanoparticles as drug carriers.

Authors:  Jun Jie Wang; Zhao Wu Zeng; Ren Zhong Xiao; Tian Xie; Guang Lin Zhou; Xiao Ri Zhan; Shu Ling Wang
Journal:  Int J Nanomedicine       Date:  2011-04-11

2.  Both FA- and mPEG-conjugated chitosan nanoparticles for targeted cellular uptake and enhanced tumor tissue distribution.

Authors:  Zhenqing Hou; Chuanming Zhan; Qiwei Jiang; Quan Hu; Le Li; Di Chang; Xiangrui Yang; Yixiao Wang; Yang Li; Shefang Ye; Liya Xie; Yunfeng Yi; Qiqing Zhang
Journal:  Nanoscale Res Lett       Date:  2011-10-25       Impact factor: 4.703

Review 3.  Bio- and Fossil-Based Polymeric Blends and Nanocomposites for Packaging: Structure⁻Property Relationship.

Authors:  Francesca Luzi; Luigi Torre; José Maria Kenny; Debora Puglia
Journal:  Materials (Basel)       Date:  2019-02-03       Impact factor: 3.623

Review 4.  Nanochitosan: Commemorating the Metamorphosis of an ExoSkeletal Waste to a Versatile Nutraceutical.

Authors:  Iyyakkannu Sivanesan; Manikandan Muthu; Judy Gopal; Nazim Hasan; Syed Kashif Ali; Juhyun Shin; Jae-Wook Oh
Journal:  Nanomaterials (Basel)       Date:  2021-03-23       Impact factor: 5.076

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.